Critical Reviews in Oncology / Hematology
Volume 43, Issue 2 , Pages 159-165 , August 2002

EORTC prostate cancer trials: what have we learnt?

  • Theo M. de Reijke

      Affiliations

    • Department of Urology, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +31-20-5666004; fax: +31-20-6919647
    • ,
  • Laurence Collette

      Affiliations

    • EORTC Data Center, Statistician, Brussels, Belgium

,Accepted 23 October 2001.

References 

  1. Jones WG, Fossa SD, Denis L, Coninx P, Glashan RW, Akdas A, et al. An EORTC Phase II study of Vindesine in advanced prostate cancer. Eur. J. Cancer Clin. Oncol. 1983;19:583–588
  2. Jones WG, Fossa SD, Bono AV, Croles JJ, Stoter G, de Pauw M, et al. Mitomycin-C in the treatment of metastatic prostate cancer: report on an EORTC phase II study. World J. Urol. 1986;4:182–185
  3. Jones WG, Fossa SD, Bono AV, Klijn JMG, de Pauw M, Sylvester R. European Organization for Research and Treatment of Cancer (EORTC) phase II study of low-dose weekly epirubicin in metastatic prostate cancer. Cancer Treat. Rep. 1987;71:1317–1318
  4. Jones WG, Fossa SD, Verbaeys AJ, et al.  Low dose fortnightly methotrexate in advanced prostate cancer. Eur. J. Cancer. 1990;26:646
  5. Newling DW, Fossa S, Tunn U, Kurth KH, de Pauw M, Sylvester R. Comparison of the effects of high dose estramustine phosphate and mitomycin C on the time to progression and length of survival of patients with progressive, advanced endocrine-independent prostatic cancer: an interim analysis of EORTC-GU Group study number 30 865. J. Steroid. Biochem. Mol. Biol. 1990;37:971–975
  6. Fossa SD, Kaasa S, da Silva FC, Suciu S, Hengeveld MW. Quality of life in prostate cancer patients. Prostate Suppl. 1992;4:145–148
  7. Aaronson NK, Ahmedzai S, Bergman B, et al.  The European Organisation for Research and Treatment of Cancer QLQ-C30. A quality-of-life instrument for use in international clinical trials in oncology. J. Natl. Cancer Inst. 1993;85:365–376
  8. Bubley GJ, Carducci M, Dahut W, et al.  Eligibility and response guidelines for Phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J. Clin. Oncol. 1999;17:3461–3467
  9. Albrecht W, Horenblas S, Marechal JM, et al.  Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy versus estramustine alone in patients with hormone escaped progressive metastatic prostate cancer. J. Urol. 1999;161:298; abstract
  10. Fossa SD, Slee PHTh, Brausi M, et al.  Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a Phase III study of the European Organization for Research and Treatment of Cancer Genitourinary Group. J. Clin. Oncol. 2001;19:62–71
  11. Pavone-Macaluso M, de Voogt HJ, Viggiano G, et al.  Comparison of diethylstilbestrol, cpa and medroxy-progesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized Phase III trial of the European Organization for Research and Treatment of Cancer. J. Urol. 1986;136:624–631
  12. Smith PH, Suciu S, Robinson MR, et al.  A comparison of the effect of diethylstilbestrol with low dose estramustine phosphate in the treatment of advanced prostatic cancer: final analysis of a Phase III trial of the European Organization for Research on Treatment of Cancer. J. Urol. 1986;136:619–623
  13. The EORTC Urological Group Smith PH, Bono A, Calais da Silva F, et al.  Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer. A subanalysis of EORTC trial 30 853.. Cancer. 1990;66(Suppl):1009–1016
  14. EORTC Urological Group Schröder FH. Treatment response criteria for prostatic cancer. Prostate. 1984;5:181–191
  15. De Voogt HJ, Suciu S, Sylvester R, Pavone-Macaluso M, Smith PH, de Pauw M. Multivariate analysis of prognostic factors in patients with advanced prostatic cancer: results from 2 European Organization for Research on Treatment of Cancer trials. J. Urol. 1989;141:883–888
  16. Robinson MR. EORTC protocol 30 805: a Phase III trial comparing orchidectomy versus orchidectomy and cyprotererone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate. Progr. Clin. Biol. Res. 1988;260:101–110
  17. Labrie F, Dupont A, Belanger A, et al.  New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clin. Invest. Med. 1982;5:267–275
  18. De Voogt HJ, Studer U, Schröder FH, Klijn JG, de Pauw M, Sylvester R. Maximum androgen blockade using LHRH agonist Buserelin in combination with short-term (2 weeks) or long-term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer. Final analysis of EORTC-GU Group trial 30 843. Eur. Urol. 1998;33:152–158
  19. Denis LJ, Keuppens F, Smith PH, et al.  Maximal androgen blockade: final analysis of EORTC Phase III trial 30 853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center. Eur. Urol. 1998;33:144–151
  20. Sylvester RJ, Denis L, de Voogt H. The importance of prognostic factors in the interpretation of two EORTC metastatic prostate cancer trials. Eur. Urol. 1998;33:134–143
  21. Prostate Cancer Trialists’ Collaborative Group . Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomized trials with 3283 deaths in 5710 patients. Lancet. 1995;346:265–269
  22. Prostate Cancer trialists'Collaborative Group . Maximum androgen blockade in advanced prostate cancer: an overview of the randomized trials. Lancet. 2000;355:1491–1498
  23. Schröder FH, Whelan P, de Reijke ThM, et al.  Metastatic prostate cancer treated by flutamide versus cyproterone acetate (EORTC 30 892). Final analysis. Eur. Urol. 1999;37(suppl):127
  24. Schröder FH, Collette L, de Reijke ThM, Whelan P. Prostate cancer treated by anti-androgens:is sexual function preserved. Br. J. Cancer. 2000;82:283–290
  25. De Reijke ThM, Keuppens FI, Whelan P, et al.  Orchiectomy and orchiectomy plus Mitomycin C for metastatic prostate cancer in patients with poor prognosis: the final results of a European Organization for Research in Cancer Genitourinary Group trial. J. Urol. 1999;162:1658–1665
  26. Fossa SD, Curran D, Aaronson NK, et al.  Quality of life of patients with newly diagnosed poor prognosis M1 prostate cancer undergoing orchiectomy without or with mitomycin C. Results from the EORTC Phase-III trial 30 893. Eur. Urol. 2000;37:541–551
  27. Goldenberg SL, Bruchovski N, Gleave ME, Sullivan LD, Akakura K. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology. 1995;45:839–844
  28. Albrecht W, Fava C, Kaiakini OB, et al. Intermittent maximal androgen blockade in patients with metastatic prostate cancer. A feasibility study. J. Urol. Submitted for the publication.
  29. The Medical Research Council Prostate Cancer Working Party Investigators Group . Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br. J. Urol. 1997;79:235–246
  30. Bolla M, Gonzalez D, Warde P, et al.  Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. New Engl. J. Med. 1997;337:295–300
  31. Bolla M, Collette L, Gonzalez D, et al. Immediate androgen suppression with external irradiation improves survival in patients with locally advanced prostate cancer. Long-term results of an EORTC Phase III randomized trial. Lancet. Submitted for the publication.
  32. Lange PH, Vessella RL. Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone. Cancer Metast. Rev. 1999;17:331–336
  33. Orr FW, Kostenuik P, Sanchez-Sweatman OH, Singh G. Mechanisms involved in the metastases of cancer to bone. Breast Cancer Res. Treatm. 1993;25:151–163
  34. Diel IJ, Solomayer EF, Bastert G. Bisphosphonates and the prevention of metastasis: first evidences from preclinical and clinical studies. Cancer. 2000;88:3080–3088

PII: S1040-8428(02)00028-8

Critical Reviews in Oncology / Hematology
Volume 43, Issue 2 , Pages 159-165 , August 2002

Article Tools